PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.89%
Revenue growth at 75-90% of MRVL's 5.89%. Bill Ackman would push for innovation or market expansion to catch up.
5.98%
Gross profit growth above 1.5x MRVL's 3.64%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
13.25%
Positive EBIT growth while MRVL is negative. John Neff might see a substantial edge in operational management.
13.25%
Positive operating income growth while MRVL is negative. John Neff might view this as a competitive edge in operations.
17.62%
Net income growth above 1.5x MRVL's 1.42%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15.87%
EPS growth of 15.87% while MRVL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
15.87%
Diluted EPS growth above 1.5x MRVL's 3.23%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.95%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.06%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
197.99%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
249.90%
FCF growth above 1.5x MRVL's 1.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
104.85%
10Y revenue/share CAGR under 50% of MRVL's 894.11%. Michael Burry would suspect a lasting competitive disadvantage.
13.16%
5Y revenue/share CAGR under 50% of MRVL's 78.63%. Michael Burry would suspect a significant competitive gap or product weakness.
6.40%
3Y revenue/share CAGR under 50% of MRVL's 22.44%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
793.32%
10Y OCF/share CAGR under 50% of MRVL's 36531.97%. Michael Burry would worry about a persistent underperformance in cash creation.
-26.42%
Negative 5Y OCF/share CAGR while MRVL is at 94.64%. Joel Greenblatt would question the firm’s operational model or cost structure.
409.15%
3Y OCF/share CAGR above 1.5x MRVL's 3.14%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
183.95%
Net income/share CAGR at 75-90% of MRVL's 241.92%. Bill Ackman would press for strategic moves to boost long-term earnings.
45.78%
Below 50% of MRVL's 3056.57%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
158.63%
3Y net income/share CAGR 75-90% of MRVL's 180.27%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
362.88%
10Y equity/share CAGR above 1.5x MRVL's 86.43%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
87.50%
5Y equity/share CAGR above 1.5x MRVL's 48.79%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
43.12%
3Y equity/share CAGR 1.25-1.5x MRVL's 34.04%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.59%
Firm’s AR is declining while MRVL shows 11.18%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-11.69%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
3.57%
Asset growth above 1.5x MRVL's 0.67%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.68%
BV/share growth above 1.5x MRVL's 1.60%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-2.42%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
3.54%
R&D growth drastically higher vs. MRVL's 6.67%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-0.39%
We cut SG&A while MRVL invests at 8.59%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.